EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia

Cristina Papayannidis iD, Elisabetta Petracci, Patrizia Zappasodi, Nicola Fracchiolla, Fabio Ciceri, Chiara Sartor, Elisa Roncoroni, Francesco Di Raimondo, Daniele Mattei, Maria Benedetta Giannini, Francesco Lanza, Michele Gottardi und 21 weitere

Cancer · 2025

DOI: 10.1002/cncr.35820 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2025. Verfasst von Cristina Papayannidis und 32 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Hauptthemen laut MEDLINE: Inotuzumab Ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Immunological, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute, Pfizer s.r.l..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B‐cell acute lymphoblastic leukemia (B‐ALL) but real‐world data are limited.

Methods

The INO‐CD22 study is a multicenter retrospective cohort study of adult patients with relapsed/refractory B‐ALL treated with IO in 24 Italian centers from 2014 to 2019, with the aim of assessing the response, survival, and toxicity of IO.

Results

Data for 73 eligible patients were obtained: the median age at the start of IO treatment was 52.7 years (I–III quartiles, 51.9–53.5 years), the median number of previous lines was three (I–III quartiles, two to four), and prior exposure to induction standard chemotherapy and blinatumomab occurred in 85% and 57.5% of cases, respectively. IO was administered following the label schedule. A 74.0% overall response rate was achieved, with a 69.8% complete remission rate and a 4.1% complete remission with incomplete hematologic reconstitution rate. The median duration of response was 4.4 months (I–III quartiles, 2.3–11.2 months). With a median follow‐up of 37.2 months, the median overall survival (OS) was 7.9 months (95% CI, 6.08–12.42 months) with a 3‐ and 5‐year OS of 21.2% (95% CI, 11.9%–32.3%) and 5.3% (95% CI, 9.6%–29.8%), respectively. Overall, 37% of patients were able to proceed to allogeneic hematopoietic stem cell transplantation. Eight patients (11.0%) experienced veno‐occlusive disease/sinusoidal obstruction syndrome; the most frequent grade ≥3 nonhematologic adverse events were liver toxicities and pneumonia (two grade 4 and one grade 5, respectively).

Conclusions

Despite the limitations of retrospective studies, the INO‐CD22 study highlights the favorable safety profile and clinical activity of IO within a real‐world context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inotuzumab OzogamicinPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Agents, ImmunologicalNeoplasm Recurrence, LocalHumansMiddle AgedFemaleMaleRetrospective StudiesAdultAgedTreatment Outcome

Stichwörter der Autor:innen

B‐cell acute lymphoblastic leukemia (B‐ALL)inotuzumab ozogamicin (IO)real‐world datarelapsed/refractory B‐ALL

Substanzen

Inotuzumab OzogamicinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.
  • Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
  • Unità Operativa of Oncohematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Unit of Hematology and Bone Marrow Transplantation, IRCCS "San Raffaele" Hospital, Milan, Italy.
  • Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.

ORCID-Profile: Cristina Papayannidis, Erika Borlenghi, Nicola Di Renzo, Mario Luppi, Felicetto Ferrara, Giovanni Marconi

Förderung

  • Ministero della Salute
  • Pfizer s.r.l.

Zitieren

APA

Papayannidis, C., Petracci, E., Zappasodi, P., Fracchiolla, N., Ciceri, F., Sartor, C., Roncoroni, E., Di Raimondo, F., Mattei, D., Giannini, M. B., Lanza, F., Gottardi, M., Del Principe, M. I., Borlenghi, E., Fumagalli, M., Vallisa, D., Sica, S., Di Renzo, N., Fabbiano, F., …, & Martinelli, G. (2025). INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia. Cancer. https://doi.org/10.1002/cncr.35820

Vancouver

Papayannidis C, Petracci E, Zappasodi P, Fracchiolla N, Ciceri F, Sartor C, et al. INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia. Cancer. 2025. doi:10.1002/cncr.35820

BibTeX
@article{Papayannidis2025,
  author = {Papayannidis, Cristina and Petracci, Elisabetta and Zappasodi, Patrizia and Fracchiolla, Nicola and Ciceri, Fabio and Sartor, Chiara and Roncoroni, Elisa and Di Raimondo, Francesco and Mattei, Daniele and Giannini, Maria Benedetta and Lanza, Francesco and Gottardi, Michele and Del Principe, Maria Ilaria and Borlenghi, Erika and Fumagalli, Monica and Vallisa, Daniele and Sica, Simona and Di Renzo, Nicola and Fabbiano, Francesco and Todisco, Elisabetta and de Fabritiis, Paolo and Luppi, Mario and Passamonti, Francesco and Corradini, Paolo and Petruzziello, Fara and Pane, Fabrizio and Ferrara, Felicetto and Mambelli, Greta and Volpi, Roberta and Frabetti, Federica and Zingaretti, Chiara and Marconi, Giovanni and Martinelli, Giovanni},
  title = {INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35820}
}
Kostenlos starten →